HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

AIDS

Volumn 14, Issue 2, 2000, Pages 163-171

  Miller, Veronica ^d,e   Ait Khaled, Mounir ^a   Stone, Chris ^a   Griffin, Philip ^a   Mesogiti, Despina ^a   Cutrell, Amy ^f   Harrigan, Richard ^b   Staszewski, Schlomo ^d   Katlama, Christine ^c   Pearce, Gillian ^a   Tisdale, Margaret ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f NONE

Author keywords

Abacavir; Drug resistance; Genotype; Phenotype; Virologic response

Indexed keywords

ABACAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; ASSAY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS RECOMBINANT;

COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0033995190     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00012     Document Type: Article

References (17)

1. 1. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41:1082-1093.
2. 2. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1098.
3. 3. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997, 41:1099-1107.
4. 4. Lanier R, Ait-Khaled M, Madison S, et al. Analysis of possible predictors of response to Abacavir (ABC) in antiretroviral-experienced adults; Comparison of viral genotype, viral phenotype, and patient treatment history. Sixth Conference on Retroviruses and Opportunistic infections. Chicago, January 1999 [abstract 134].
5. 5. Ait-Khaled M, Stone C, Mesogiti D, Purdon S, Vernazza P for the CNA3002 International Study Group. Genotype and phenotype of HIV-1 RT in ART experienced adults prior to and following therapy with Ziagen (Abacavir, ABC) added to stable background therapy (ABC + SBG). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 114].
6. 6. Miller V, Stürmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998, 12:705-712.
7. 7. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 4:269:696-699.
8. 8. Harrigan R, Stone C, Griffin P, et al. Resistance profile of the HIV-1 RT inhibitor abacavir (ABC, 1592U89) after monotherapy and combination therapy. J Infect Dis in press.
9. 9. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatmentnaïve subjects. AIDS 1998, 12:F197-F202.
10. 10. Staszewski S, Keiser P, Gathe J, et al. Ziagen/Combivir is equivalent to Indinavir/Combivir in antiretroviral therapy (ART) naïve adults at 24 weeks (CNA3005). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract 20].
11. 11. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 14:365:671-673.
12. 12. Hertogs K, Bethune M, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
13. 13. Perrin L. Transmission of drug-resistant HIV. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract S35],
14. 14. Schuurman R, Nijhuis M, van Leewen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
15. 15. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (AZT) versus AZT plus 3TC in previously untreated patients. AIDS 1996, 10: 975-981.
16. 16. Katlama C, Clotet B, Plettenberg A, et al. Intensification of stable background antiretroviral therapy (ART) with Abacavir: Preliminary 16 Week data. Fourth International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract OP2.3].
17. 17. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of HIV-1 resistant to 3′-thiacytidine inhibitors due to a mutation in the 'YMDD' region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.